117 related articles for article (PubMed ID: 11072027)
1. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Kabarowski JH; Witte ON
Stem Cells; 2000; 18(6):399-408. PubMed ID: 11072027
[TBL] [Abstract][Full Text] [Related]
2. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
[TBL] [Abstract][Full Text] [Related]
3. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
4. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cells in chronic myeloid leukemia.
Petzer AL; Gunsilius E
Arch Med Res; 2003; 34(6):496-506. PubMed ID: 14734089
[TBL] [Abstract][Full Text] [Related]
8. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
[TBL] [Abstract][Full Text] [Related]
9. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
11. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
[TBL] [Abstract][Full Text] [Related]
12. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
Ren R
Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
[TBL] [Abstract][Full Text] [Related]
13. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
15. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
16. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
Wertheim JA; Miller JP; Xu L; He Y; Pear WS
Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.
Marley SB; Gordon MY
Clin Sci (Lond); 2005 Jul; 109(1):13-25. PubMed ID: 15966868
[TBL] [Abstract][Full Text] [Related]
18. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
19. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of transformation by the BCR-ABL oncogene.
Sattler M; Griffin JD
Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]